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biology, this progress has not matched what we know about
the biology underlying the symptoms and toxic effects that
therapies produce. These adverse symptoms can cause sub-
stantial discomfort, functional loss and distress to patients;
they limit treatment tolerability, and can persist indefinitely
in post-treatment survivorship [1]. Effective control of treat-
ment-related symptoms could enhance therapeutic out-
comes by improving patient health status, minimising
toxicities that impair function, increasing adherence to cura-
tive treatments, maintaining health-related quality of life and
potentially increasing survival. A mechanistic understanding
of treatment-related symptoms would be of benefit in drug
development, drug evaluation and early integration of appro-
priate supportive care in treatment planning. This presenta-
tion will present steps in a translational pathway for
understanding and controlling treatment-related symptoms
Cytotoxic therapies (chemotherapy, radiation) are ex-
pected to produce symptoms, because normal tissue and
function are disrupted as cancer cells are killed. Targeted
anticancer therapies were expected to destroy cancer cells
specifically and therefore to cause less general toxicity, yet
different and often severe toxicities have emerged, with each
novel agent having its own unique toxicity profile
1. A translational pathway for treatment-
related symptoms
The difficulties inherent in translating laboratory findings
into patient benefit are widely recognised in every disease
area. In 2005, the National Cancer Institute created a Transla-
tional ResearchWorking Group to speed the application of the
findings of molecular oncology to patient care [2]. In response,
the working group developed a model for a translational re-
search pathway. Although the model was developed for new
curative therapy, a similar model might be used to conceptu-
alise how to move the collective basic and clinical symptom
research into the clinic. A schematic illustrating such a trans-lational pathway for symptom research is presented in Fig. 1,
using fatigue as an example [3].
Early components of the pathway include discovery re-
search steps and decision points based on longitudinal obser-
vational studies of patients, including patient interviews and
determination of specific symptoms associated with disease,
stage or treatment. Correlational studies showing the co-var-
iation of biomarkers (such as inflammation) and symptom
expression, although an important step, do not provide suffi-
cient information on the mechanistic basis of symptom pro-
duction for the development of potential agents targeted at
symptom control. Instead, hypotheses about mechanisms
underlying symptom expression are developed through
examination of longitudinal symptom data, clinical corre-
lates, biomarkers (genes, proteins) and brain imaging data ob-
tained from patients. These hypothesised mechanisms are
then tested in animal models. Candidate agents that may af-
fect these mechanisms are developed in the laboratory, then
applied in animal models of the specific disease. Agents that
give some signal of effectiveness in preventing or reducing
the specific cancer without excessive toxicity then move for-
ward into patient research.
For some symptoms, such as bone-related pain, sufficient
progress has been made in animal models to provide a basic
understanding of the mechanisms involved and to test agents
that might have a clinical benefit. In contrast, much less is
known about the development of animal models of such
symptoms as treatment-related cognitive impairment, fati-
gue and treatment-related distress. Animal models of cogni-
tive impairment and reduced motivation are available, but
the effects on these models of having cancer and being trea-
ted for cancer have not been assessed.
Biomedical research is largely dependent on having ani-
mal models of the targets of interest. The same applies to
symptom science, where exploratory and confirmatory stud-
ies in humans can be conducted in parallel in animal models
of symptom translational research in a bedside-to-bench and
bench-to bedside collaboration. Fatigue research is an excel-
Fig. 1 – Discovery and translational pathway for cancer
symptom research.
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tients describe—lack of motivation, increased cognitive prob-
lems and decreased motivation to be social—can be modelled
in animals, and many are typical components of what is stud-
ied in animals as ‘sickness behaviour’ [4]. Animal models of
disease and treatment-induced cancer pain have suggested
both potential mechanisms of pain development and novel
ways of treating cancer pain. Animal models also are neces-
sary for preclinical testing of symptom agents. Generating
hypotheses about symptom expression can lead to early
phase trials in patients. Animal models that reflect symptom-
atic behaviours in a way that ‘makes sense’ to both patients
and clinicians need to be developed on the basis of patient
self-report of symptom severity and linked to animal behav-
ioural, central nervous system (CNS) and systemic changes
that reflect these symptoms. A critical step throughout the
process is to determine the interaction between pathwaysthat modulate disease and those that modulate symptoms,
to ensure that symptom control does not compromise cura-
tive benefit.
Cancer-related symptoms are affected not only by treat-
ment but also by individual host characteristics. There is sub-
stantial variation in the degree to which symptoms will
impair patients, much like there is variance in the ability of
a given drug to control cancer. Being able to predict this risk
would benefit personalised cancer care. Potential predictors
of high behavioural toxicity can be studied using advanced
molecular genetic technologies. Analysis of genetic predictors
for symptom occurrence and severity during treatment will
help us to understand the biological basis of symptoms, iden-
tify susceptible individuals, develop tests with prognostic
power, design novel drug targets and predict therapeutic
outcomes.
Finally, methods to reduce treatment-related symptoms
will require early clinical investigation. Too many large-scale
phase III symptom-focused clinical trials have been per-
formed with negative results. Potential reasons for this in-
clude (a) lack of knowledge of the potential mechanisms
producing the symptoms, (b) inadequate preclinical testing
and (c) small early trials in patients to detect a signal. Just
as with curative therapies, early use of adaptive clinical trial
design could be employed to sort among agents that show
promise for mitigating symptoms and to quickly cull those
that do not [5].
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